Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palisade Bio Inc.

1.00
+0.08258.99%
Post-market: 0.9350-0.0650-6.50%19:57 EDT
Volume:1.46M
Turnover:1.48M
Market Cap:2.77M
PE:-0.07
High:1.10
Open:0.9600
Low:0.9536
Close:0.9175
Loading ...

Palisade Bio Begins Dosing Ulcerative Colitis Patients in PALI-2108 Trial

MT Newswires Live
·
14 Mar

Palisade Bio: No Serious Adverse Events & No Treatment-Emergent Adverse Events Related to Laboratory Values or Ekgs Seen to Date

THOMSON REUTERS
·
14 Mar

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/B Study of Pali-2108

THOMSON REUTERS
·
14 Mar

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

GlobeNewswire
·
14 Mar

Palisade Bio Participates in Virtual Investor “What This Means” Segment

GlobeNewswire
·
04 Mar

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

GlobeNewswire
·
10 Feb

Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

GlobeNewswire
·
29 Jan

Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

GlobeNewswire
·
22 Jan

Palisade Bio Completes All Five Sad Cohorts and Advances to Mad Cohorts of Phase 1a/B Study of Pali-2108 for Treatment of Ulcerative Colitis

THOMSON REUTERS
·
16 Jan

Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

GlobeNewswire
·
16 Jan

BRIEF-Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
04 Jan

Palisade Bio appoints Feagan to Clinical Advisory Board

TIPRANKS
·
17 Dec 2024

Palisade Bio Appoints Brian Feagan, Md, Frcpc, to Its Clinical Advisory Board

THOMSON REUTERS
·
17 Dec 2024

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced at-Market Under Nasdaq Rules

THOMSON REUTERS
·
13 Dec 2024

Palisade Bio Inc - Preliminary Pk Data Show Delayed Release of Pde4 Inhibitor

THOMSON REUTERS
·
03 Dec 2024

Palisade Bio Inc - No Treatment Related Adverse Events in First Three Sad Cohorts

THOMSON REUTERS
·
03 Dec 2024